Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Haematologica|November 14, 2022
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patientsSpyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, et al.Blood Advances|July 12, 2019
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAllistair A Abraham, Tami D John, Michael D Keller, et al.Blood|May 16, 2015
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationXiaoou Zhou, Gianpietro Dotti, Robert A Krance, et al.Blood|April 23, 2014
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgeneXiaoou Zhou, Antonio Di Stasi, Siok-Keen Tey, et al.Nature Medicine|January 2, 2026
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trialBenjamin L Musher, Spyridoula Vasileiou, Brandon G Smaglo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationIfigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.Blood|September 14, 2013
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyConrad Russell Y Cruz, Kenneth P Micklethwaite, Barbara Savoldo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.Pageof 3